Lunit Achieves Major Milestone with Over 1 Million Mammograms in the US After Volpara Acquisition

Lunit Reaches a Significant Milestone in U.S. Mammography

On May 19, 2025, Lunit (KRX:328130.KQ), a prominent company innovating in artificial intelligence for cancer diagnostics and therapeutics, announced an impressive achievement: over one million mammograms have been processed in the United States in just one year post their acquisition of Volpara Health Technologies. This milestone reflects a significant advancement in the company's strategy to expand its footprint in the North American healthcare sector.

Since the acquisition, Lunit has rapidly broadened its operations and now boasts its AI solutions, including Lunit INSIGHT for digital breast tomosynthesis and mammography analysis, available at over 200 imaging facilities across the U.S. Currently, around 350 to 400 radiologists are utilizing Lunit's technology, showcasing the rapid adoption and trust in AI-driven healthcare solutions.

This joint venture between Lunit and Volpara has resulted in a striking statistic: the collaboration now underpins more than one million annual mammograms in North America, a clear indicator of Lunit's solidifying status in the medical imaging market. Some of their noteworthy collaborators include respected healthcare entities such as Rezolut, SimonMed Imaging, and UC Davis Health.

Lunit and Volpara have also made strides towards creating a comprehensive Ecosystem for Cancer Detection and Care, showcased at RSNA 2024. This Ecosystem aims to integrate various AI technologies capable of detecting lesions, optimizing workflows, maintaining quality control, and enhancing patient engagement. The end goal is to provide clinicians with actionable insights and scalable solutions, streamlining the entire cancer care continuum.

During the RSNA 2024 conference, the complementary capabilities of Lunit INSIGHT Risk with Volpara Risk Pathways were highlighted. This integration is designed to use imaging and clinical data together to personalize breast cancer risk assessments. A prototype demonstrated how these two systems could synergistically predict the likelihood of developing breast cancer within one to five years, allowing for earlier interventions and more tailored care, ultimately setting new standards for breast cancer screening and management practices.

Brandon Suh, CEO of Lunit, shared, "The successful integration of Lunit and Volpara has accelerated our mission to transform cancer diagnostics globally, and the momentum we've built in the United States marks just the beginning. By combining Lunit's AI innovation with Volpara's breast health expertise, we're delivering a new standard of comprehensive support for clinicians—enhancing early detection, improving screening quality, optimizing workflows, and ultimately helping providers deliver better outcomes for patients worldwide."

The achievements in the past year not only signal a monumental stride in Lunit's operations but also herald a new era in cancer detection and care, where AI is set to redefine traditional standards. Lunit is positioned for continued expansion in the U.S., fostering growth through advanced AI-driven solutions and dedicated clinical support.

Lunit, established in 2013, is committed to combatting cancer with AI. Its solutions are already in use across over 4,800 medical facilities in more than 55 countries, supported by clinical studies published in top-tier journals like The Lancet Digital Health. Lunit's initiatives remain at the forefront of ensuring accurate diagnosis and personalized treatment options for patients globally, with a firm commitment to harnessing AI in the battle against cancer.